Westlake Village-based Sienna Biopharmaceuticals reported a $16.8 million net loss, or 82 cents per share, for the quarter ended Sept. 30, a slight increase from the previous third quarter as it increased trials and manufacturing for its dermatology products. A 16 percent increase in operating costs came primarily from development costs for two treatments for…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
